SMPDL3A Inhibitors
Chemical inhibitors of SMPDL3A encompass a variety of compounds that interfere with the protein's function through different mechanisms. Chloroquine, a lysosomotropic agent, can disrupt SMPDL3A activity by raising the pH within acidic vesicles, which is a condition unfavorable for the enzymatic activity of SMPDL3A. Tricyclic antidepressants such as Imipramine and Desipramine can inhibit SMPDL3A by competing for binding sites or allosteric sites that are crucial for its enzymatic function. Their structure allows them to bind to regions that are essential for catalysis or regulation of the enzyme's activity. Fluoxetine and Sertraline, both selective serotonin reuptake inhibitors, can also inhibit SMPDL3A by altering intracellular signaling pathways, particularly those associated with lipid rafts where SMPDL3A is localized. This disruption can modify the activity of SMPDL3A, leading to a decrease in its function within the cell.
Additional chemical inhibitors include Amiodarone and Propranolol, can inhibit SMPDL3A by interfering with lipid membrane interactions and modulating membrane lipid composition, respectively, affecting the protein's activity. Bepridil can affect SMPDL3A indirectly by influencing calcium homeostasis, which plays a part in various calcium-dependent cellular processes related to SMPDL3A. Tamoxifen interferes with SMPDL3A through mechanisms involving estrogen receptor-related pathways, which are implicated in the regulation of SMPDL3A. Perhexiline can alter the lipid environment of SMPDL3A by affecting fatty acid metabolism. Lastly, Haloperidol and Indomethacin can inhibit SMPDL3A by impacting the lipid raft-associated cellular signaling and arachidonic acid pathway, respectively, both of which are critical for maintaining the proper function and localization of SMPDL3A within the cellular context. Each of these inhibitors can modulate the activity of SMPDL3A through distinct but converging pathways that ultimately lead to a decrease in the protein's enzymatic activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine is a known lysosomotropic agent that accumulates in acidic vesicles and can raise their pH, potentially inhibiting SMPDL3A by impairing the acidification necessary for its optimal enzymatic activity. | ||||||
Imipramine | 50-49-7 | sc-507545 | 5 mg | $190.00 | ||
Imipramine is a tricyclic antidepressant that also inhibits acid sphingomyelinase (ASM). Given that SMPDL3A has similar domain architecture to ASM, Imipramine can inhibit SMPDL3A by competing for similar binding sites or allosteric sites that modulate enzymatic activity. | ||||||
Desipramine hydrochloride | 58-28-6 | sc-200158 sc-200158A | 100 mg 1 g | $65.00 $115.00 | 6 | |
Desipramine, another tricyclic antidepressant, functions similarly to Imipramine by inhibiting ASM and can inhibit SMPDL3A by binding to conserved regions involved in catalysis or enzyme regulation. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $312.00 | 9 | |
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and has been shown to inhibit ASM. It may inhibit SMPDL3A by altering intracellular signaling pathways that involve lipid rafts where SMPDL3A is localized, altering its activity. | ||||||
Amiodarone | 1951-25-3 | sc-480089 | 5 g | $312.00 | ||
Amiodarone is an antiarrhythmic agent that also inhibits ASM. Its structural similarity to other known SMPDL3A inhibitors suggests it can inhibit SMPDL3A by interfering with lipid membrane interactions essential for SMPDL3A's activity. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-blocker that has been reported to inhibit ASM. It may inhibit SMPDL3A by modulating membrane lipid composition and signaling pathways where SMPDL3A is active. | ||||||
Bepridil | 64706-54-3 | sc-507400 | 100 mg | $1620.00 | ||
Bepridil is a calcium channel blocker with ASM inhibitory activity. Its ability to inhibit SMPDL3A could be due to its effects on calcium homeostasis, indirectly influencing SMPDL3A's activity in calcium-dependent cellular processes. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Tamoxifen, a selective estrogen receptor modulator, has been shown to inhibit ASM. It might inhibit SMPDL3A by binding to estrogen receptor-related pathways that are also implicated in the regulation of SMPDL3A. | ||||||
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $184.00 | ||
Perhexiline is an antianginal medication that inhibits carnitine palmitoyltransferase-1, which is involved in fatty acid metabolism. It may inhibit SMPDL3A by altering the lipid environment in which SMPDL3A operates. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol is an antipsychotic known to inhibit ASM. Its inhibition of SMPDL3A may occur through its impact on lipid raft-associated cellular signaling, which is crucial for SMPDL3A's enzymatic function. | ||||||